Demographic Characteristics of Patient Groups According to the 1-Year Clinical Follow-up Diagnosis
| Clinical diagnosis | F/M (n) | Age (y) | Symptom duration (y) | Clinical follow-up (mo) | H&Y score | UPDRS-III score | MMSE score |
| LBD | 16/18 | 65.0 (13.7) | 3.6 (2.5) | 12.1 (6.2) | 2.7 (1.2)* | 29.8 (13.7) | 26.4 (4.6) |
| PD | 10/13 | 61.6 (14.6)† | 4.1 (2.2) | 10.8 (6.1) | 2.5 (1.2)‡ | 28.7 (14.1) | 28.2 (2.4)§ |
| PDD/DLB | 6/5 | 72.0 (8.4)c | 2.3 (2.6) | 14.6 (5.8) | 3.1 (1.2) | 32.0 (13.3) | 22.9 (5.7)§ |
| APS | 23/21 | 67.9 (8.5) | 3.3 (1.9) | 11.3 (4.4) | 3.5 (0.9)* | 33.1 (14.8) | 26.7 (3.6) |
| MSA | 8/5 | 65.5 (7.1) | 3.5 (2.0) | 9.6 (3.1) | 3.5 (0.7)‡ | 33.3 (15.6) | 28.4 (1.7)§ |
| PSP/CBD | 15/16 | 68.9 (8.9) | 3.2 (1.8) | 12.1 (4.7) | 3.5 (1.0)‡ | 33.0 (14.7) | 26.0 (4.0) |
↵* Wilcoxon test LBD vs. APS, P = 0.002.
↵† ANOVA across subgroups, P = 0.029, post hoc Tukey-Kramer honestly significant difference test indicated significantly higher age in PDD/DLB than in PD (P < 0.05).
↵‡ Kruskal–Wallis test across subgroups, P = 0.071, post hoc Wilcoxon test indicated significantly higher H&Y score in MSA (corrected P = 0.03) and PSP/CBD (corrected P = 0.01) than in PD.
↵§ ANOVA across subgroups, P = 0.0009, post hoc Tukey-Kramer honestly significant difference test indicated significantly lower MMSE in PDD/DLB than in PD and MSA (P < 0.05).
UPDRS-III = Unified Parkinson Disease Rating Scale, part III (motor score).
Data are given as mean value followed by SD in parentheses, except for sex (F/M). Clinical follow-up refers to time between PET imaging and clinical diagnosis; other data refer to time of PET imaging, except MMSE: scores were available in 67 patients, in 23 patients only at follow-up. In the latter, 17 patients still showed normal scores (≥27). Availability of MMSE data did not differ between patient groups (P > 0.1).